<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272830</url>
  </required_header>
  <id_info>
    <org_study_id>Summa-09136</org_study_id>
    <nct_id>NCT01272830</nct_id>
  </id_info>
  <brief_title>Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements</brief_title>
  <acronym>Apatone-B</acronym>
  <official_title>A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IC-MedTech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Summa Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crystal Clinic Orthopaedic Center LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IC-MedTech Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being conducted to determine if taking oral (by mouth in pill form)
      Apatone®B (a combination of Vitamins C and K3) will reduce chronic joint discomfort and
      improve function of non-infected symptomatic postoperative total joint replacements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To perform a prospective, randomized, double-blind clinical trial to determine if oral
      Apatone®B, an amalgam of vitamins C and K3, has a therapeutic efficacy beyond the
      conservative care customarily used to reduce inflammatory synovitis and to increase the
      functional capacity of proven non-infected symptomatic postoperative total joint
      replacements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Visual Analog Scale (VAS)</measure>
    <time_frame>13-weeks</time_frame>
    <description>Pain Visual Analog Scale (VAS)
Scale range (0-100) A higher VAS score indicate worse knee pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surrogate Endpoint Markers (SEBs)</measure>
    <time_frame>13 weeks</time_frame>
    <description>HSS = Hospital for Special Surgery Knee Score , KSS = Knee Society Knee Score.
Scale range HSS total: 100-90 Excellent; 80-89 Very Good; 70-79 Good; 60-69 Fair; below 60 Poor
Scale range HSS pain walking: No Pain 15; Mild Pain 10; Moderate Pain 5; Severe Pain 0 (**this is an element of the HSS total)
Scale range KSS: 80-100 Excellent; 70-79 Good; 60-69 Fair; below 60 Poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TGFBeta Levels</measure>
    <time_frame>Baseline and 13 Weeks</time_frame>
    <description>The final synovial aspirates obtained from the symptomatic knee of each subject were analyzed using Quantikine and Pyrilinks-D enzyme-linked immunosorbent assay kits from R&amp;D Systems (Minneapolis, MN) and Metra Biosystems (Mountain View, CA), respectively.
Lower TGFBeta concentrations represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deoxypyridinoline Levels</measure>
    <time_frame>Baseline and 13 Weeks</time_frame>
    <description>The final synovial aspirates obtained from the symptomatic knee of each subject were analyzed using Quantikine and Pyrlinks-D enzyme-linked immunosorbent assay kits from R&amp;D Systems(minneapolis, MN) and Metra Biosystems (Mountain View, CA) respectively.
Lower DPD concentrations represent a better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Edematous</condition>
  <condition>Synovitis</condition>
  <condition>Foreign Body Reaction</condition>
  <condition>Osteolysis</condition>
  <arm_group>
    <arm_group_label>oral Apatone®B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An amalgam of Vitamins C &amp; K3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsule of similar appearance and taste without Apatone®B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two capsules taken twice daily with meals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatone®B</intervention_name>
    <description>Two capsules taken twice daily with meals</description>
    <arm_group_label>oral Apatone®B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postoperative Total joint replacement with osteoarthritis as the underlying pathology

          -  Proven non-infected symptomatic Total Joint Arthroplasty (TJA) (joint implanted for
             &gt;12 months post-op)

          -  Age (50 to 85 years of age); based on a 10% trim of the age distribution for Summa
             Health System TJAs (7/1/08-6/30/2009).

        Exclusion Criteria:

          -  An infection of any kind (prior to, or during the study)

          -  Rheumatoid arthritis as the underlying pathology

          -  Cortisone injection received &lt;6 months prior to study enrollment

          -  Insulin dependent diabetes

          -  Diagnosed immunodeficiency

          -  On dialysis or have poor kidney function

          -  Anti-coagulant medication (e.g., Coumadin or &gt;100mg of Aspirin daily)

          -  Anti-seizure medication (e.g., Dilantin)

          -  Steroidal medication (e.g., Prednisone, Advair or Symbicort)

          -  NSAIDS (e.g., Celebrex or Toradol); a 14-day washout period will be allowed

          -  bisphosphonates (e.g., Fosamax, Actonel, Aredia, Didronel, Boniva or Reclast)

          -  hormonal therapy (e.g., Estrogen, Progesterone or Testosterone)

          -  Cancer (active or in remission)

          -  Planned concurrent vitamins exceeding a standard daily multivitamin or exceeding the
             Recommended Daily Allowance (RDA) for individual vitamins if used alone; a 72 hour
             wash out period will be allowed

          -  A glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Pregnant or lactating; females who are in their reproductive years must have a
             negative serum pregnancy

          -  Lactose intolerant

          -  Citric acid intolerant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Bear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Crystal Clinic Orthopaedic Center LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark W Kovacik, BS</last_name>
    <role>Study Director</role>
    <affiliation>Summa Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <results_first_submitted>July 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2018</results_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total joint arthroplasty</keyword>
  <keyword>synovitis</keyword>
  <keyword>ALVAL (Aseptic Lymphocyte-Dominant Vasculitis-Associated Lesion)</keyword>
  <keyword>osteolysis</keyword>
  <keyword>periprosthetic metallosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Synovitis</mesh_term>
    <mesh_term>Osteolysis</mesh_term>
    <mesh_term>Foreign Bodies</mesh_term>
    <mesh_term>Foreign-Body Reaction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 57 subjects were consented to participate.</recruitment_details>
      <pre_assignment_details>Following consenting, 6 subjects did not meet the study inclusion/exclusion criteria, thus never received the study drug.
1 - Abnormal Liver Panel: very low Hemoglobin/Hematocrit levels
1 - Glucose-6-phosphate dehydrogenase (G6PD) deficiency
3 - X-rays revealed loose or mal-positioned component(s)
1 - Prescribed steroids prior to study drug</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Apatone®B</title>
          <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Apatone®B</title>
          <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="9.5"/>
                    <measurement group_id="B2" value="65.4" spread="9.6"/>
                    <measurement group_id="B3" value="63.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.7" spread="20.4"/>
                    <measurement group_id="B2" value="100" spread="16.8"/>
                    <measurement group_id="B3" value="99" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.7" spread="9.9"/>
                    <measurement group_id="B2" value="169.8" spread="8.6"/>
                    <measurement group_id="B3" value="170.6" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time elapsed since TKA</title>
          <description>TKA - Total Knee Arthroplasty</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.9"/>
                    <measurement group_id="B2" value="4.0" spread="3.3"/>
                    <measurement group_id="B3" value="3.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Pain Visual Analog Scale (VAS)</title>
          <description>VAS Scale range (0-100 )
Higher VAS score indicate worst knee pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="24.1"/>
                    <measurement group_id="B2" value="46.8" spread="24.9"/>
                    <measurement group_id="B3" value="51.4" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Visual Analog Scale (VAS)</title>
        <description>Pain Visual Analog Scale (VAS)
Scale range (0-100) A higher VAS score indicate worse knee pain</description>
        <time_frame>13-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apatone®B</title>
            <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Visual Analog Scale (VAS)</title>
          <description>Pain Visual Analog Scale (VAS)
Scale range (0-100) A higher VAS score indicate worse knee pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="24.1"/>
                    <measurement group_id="O2" value="46.8" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="27.4"/>
                    <measurement group_id="O2" value="39.1" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0063</p_value>
            <p_value_desc>Significance threshold p&lt;0.05</p_value_desc>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes from baseline data</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significant threshold p&lt;0.05</p_value_desc>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surrogate Endpoint Markers (SEBs)</title>
        <description>HSS = Hospital for Special Surgery Knee Score , KSS = Knee Society Knee Score.
Scale range HSS total: 100-90 Excellent; 80-89 Very Good; 70-79 Good; 60-69 Fair; below 60 Poor
Scale range HSS pain walking: No Pain 15; Mild Pain 10; Moderate Pain 5; Severe Pain 0 (**this is an element of the HSS total)
Scale range KSS: 80-100 Excellent; 70-79 Good; 60-69 Fair; below 60 Poor</description>
        <time_frame>13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apatone®B</title>
            <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Surrogate Endpoint Markers (SEBs)</title>
          <description>HSS = Hospital for Special Surgery Knee Score , KSS = Knee Society Knee Score.
Scale range HSS total: 100-90 Excellent; 80-89 Very Good; 70-79 Good; 60-69 Fair; below 60 Poor
Scale range HSS pain walking: No Pain 15; Mild Pain 10; Moderate Pain 5; Severe Pain 0 (**this is an element of the HSS total)
Scale range KSS: 80-100 Excellent; 70-79 Good; 60-69 Fair; below 60 Poor</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HSS Pain Walking- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="5.4"/>
                    <measurement group_id="O2" value="6.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HSS Pain Walking-13 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="6.2"/>
                    <measurement group_id="O2" value="7.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HSS Total-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="14.3"/>
                    <measurement group_id="O2" value="71.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HSS Total-13 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="16.7"/>
                    <measurement group_id="O2" value="74.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KSS Total Pain-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="19.4"/>
                    <measurement group_id="O2" value="59.0" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KSS Total Pain-13 Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="20.1"/>
                    <measurement group_id="O2" value="63.0" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data (HSS pain walking)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0226</p_value>
            <p_value_desc>Significance threshold p&lt;0.5</p_value_desc>
            <method>paired</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data (HSS total score)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0375</p_value>
            <p_value_desc>Significance threshold P&lt;0.05</p_value_desc>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data (KSS knee pain)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0391</p_value>
            <p_value_desc>Significance threshold p&lt;0.05</p_value_desc>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes from baseline data (HSS pain walking)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2137</p_value>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data (HSS total score)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1312</p_value>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data (KSS knee pain)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1578</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TGFBeta Levels</title>
        <description>The final synovial aspirates obtained from the symptomatic knee of each subject were analyzed using Quantikine and Pyrilinks-D enzyme-linked immunosorbent assay kits from R&amp;D Systems (Minneapolis, MN) and Metra Biosystems (Mountain View, CA), respectively.
Lower TGFBeta concentrations represent a better outcome.</description>
        <time_frame>Baseline and 13 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apatone®B</title>
            <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
          </group>
        </group_list>
        <measure>
          <title>TGFBeta Levels</title>
          <description>The final synovial aspirates obtained from the symptomatic knee of each subject were analyzed using Quantikine and Pyrilinks-D enzyme-linked immunosorbent assay kits from R&amp;D Systems (Minneapolis, MN) and Metra Biosystems (Mountain View, CA), respectively.
Lower TGFBeta concentrations represent a better outcome.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3197.4" spread="2793.5"/>
                    <measurement group_id="O2" value="2089.2" spread="2879.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2572.2" spread="2879.7"/>
                    <measurement group_id="O2" value="1572.2" spread="1803.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes from baseline data</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0083</p_value>
            <p_value_desc>Significance threshold p&lt;0.05</p_value_desc>
            <method>t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Significant threshold p&lt;0.05</p_value_desc>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deoxypyridinoline Levels</title>
        <description>The final synovial aspirates obtained from the symptomatic knee of each subject were analyzed using Quantikine and Pyrlinks-D enzyme-linked immunosorbent assay kits from R&amp;D Systems(minneapolis, MN) and Metra Biosystems (Mountain View, CA) respectively.
Lower DPD concentrations represent a better outcome</description>
        <time_frame>Baseline and 13 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apatone®B</title>
            <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Deoxypyridinoline Levels</title>
          <description>The final synovial aspirates obtained from the symptomatic knee of each subject were analyzed using Quantikine and Pyrlinks-D enzyme-linked immunosorbent assay kits from R&amp;D Systems(minneapolis, MN) and Metra Biosystems (Mountain View, CA) respectively.
Lower DPD concentrations represent a better outcome</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="6.0"/>
                    <measurement group_id="O2" value="5.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.5"/>
                    <measurement group_id="O2" value="6.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline data</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Significance threshold p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes from baseline data</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>paired t-test</method>
            <method_desc>Significant threshold p&lt;0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All adverse events (AEs) were classified by the investigator with respect to severity (mild, moderate, severe and potentially life threatening). No AEs classified as potentially life threatening were reported during the course of this study, nor were there any deaths.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Apatone®B</title>
          <description>An amalgam of Vitamins C &amp; K3
Apatone®B: Two capsules taken twice daily with meals</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral capsule of similar appearance and taste without Apatone®B
Placebo: Two capsules taken twice daily with meals</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain – hospitalization</sub_title>
                <description>Outcome - not recovered, ongoing. Did not finish study; revision knee surgery elected before trial completion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13th week elevated PT, PTT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Repeated PT, PTT one week later</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall outdoors, hit head</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pulled muscle right knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Slipped on ice; cracked rib</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Knee discomfort left and right</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Entire body ached</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Extreme knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Painful knee aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Right knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Swelling of knees</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Knee discomfort right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Knee pain left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Right calf pain, possible blood clot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Published articles to be reviewed/approved by IC-MedTech prior to publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>limited accrual due to meeting stringent study inclusion/exclusion criteria.Stringent inclusion/exclusion created to allow SEB analyses w/o interference or artifacts,&amp; not due to study drug issues,interaction or limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Bear, MD</name_or_title>
      <organization>Clinic Orthopaedic Center</organization>
      <phone>330-375-3906</phone>
      <email>kovacikm@summahealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

